Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5,433 Mln
Revenue (TTM)
$1,731 Mln
Net Profit (TTM)
$0 Mln
ROE
-77.4 %
ROCE
-- %
P/E Ratio
7.7
P/B Ratio
1743.3
Industry P/E
--
EV/EBITDA
6.9
Div. Yield
0 %
Debt to Equity
-2.4
Book Value
$--
EPS
$8.5
Face value
--
Shares outstanding
82,774,730
CFO
$-1,382.00 Mln
EBITDA
$-1,701.30 Mln
Net Profit
$-3,012.65 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PTC Therapeutics (PTCT)
| -10.8 | -0.6 | -10.8 | 45.4 | 11.8 | 6.6 | 25.9 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
PTC Therapeutics (PTCT)
| 68.3 | 63.1 | -27.8 | -4.2 | -34.7 | 27.1 | 39.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PTC Therapeutics (PTCT)
|
67.8 | 5,433.3 | 1,730.7 | 682.6 | 49.0 | -104.7 | 7.7 | 1,743.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna... and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey. Address: 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059 Read more
CEO & Director
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
CEO & Director
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Headquarters
Warren, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of PTC Therapeutics Inc (PTCT) is $67.77 (NASDAQ) as of 02-Apr-2026 16:00 EDT. PTC Therapeutics Inc (PTCT) has given a return of 11.84% in the last 3 years.
The P/E ratio of PTC Therapeutics Inc (PTCT) is 7.65 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
8.98
|
-29.85
|
|
2024
|
-9.59
|
-3.17
|
|
2023
|
-3.32
|
-2.54
|
|
2022
|
-4.96
|
-7.99
|
|
2021
|
-5.37
|
1,957.49
|
The 52-week high and low of PTC Therapeutics Inc (PTCT) are Rs 87.50 and Rs 35.95 as of 04-Apr-2026.
PTC Therapeutics Inc (PTCT) has a market capitalisation of $ 5,433 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in PTC Therapeutics Inc (PTCT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.98
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.